TOLREMO therapeutics AG

TOLREMO therapeutics AG is a Swiss biotechnology company dedicated to overcoming cancer drug resistance by targeting non-oncogene addiction [1, 2, 4]. The company utilizes a proprietary phenotypic screening platform to identify and block transcriptional escape pathways that allow cancer cells to evade treatment [1, 3]. Their lead clinical candidate, TT125-802, is an orally available, selective small-molecule inhibitor of the CBP/p300 bromodomain [3, 8]. By disrupting these epigenetic regulators, the therapy prevents transcriptional reprogramming, a process that functions parallel to primary oncogene signaling and contributes to both primary and acquired drug resistance [1, 3, 8].

This approach addresses a critical barrier in oncology where standard targeted therapies often fail due to tumor evolution and resistance [3, 6]. By combining TT125-802 with existing treatments, the company aims to enhance the durability and effectiveness of cancer care, specifically in solid tumors and hematological malignancies [1, 8]. The compound has demonstrated a differentiated safety profile, including the absence of common toxicities associated with other bromodomain inhibitors, which supports its utility in combination regimens [8]. TOLREMO is currently advancing TT125-802 through clinical trials, including Phase 1 studies, with U.S. FDA Fast Track designations for specific patient populations with non-small cell lung cancer [8].